Introduction: Severe hypoglycemic events
diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) in the PREDICTIVE study. quality of life, adherence to therapy and workplace productivity [1] [2] [3] [4] [5] [6] . They represent a significant clinical concern and source of distress in patients with both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) [7] [8] [9] [10] [11] , both for insulin users as well as for patients using only oral antidiabetic drugs (OADs) [12] [13] [14] [15] . Hypoglycemic events or fear of such events has been identified as the major treatment-limiting factors in titrating insulin to optimal glycemic targets in T2DM [16, 17] . A recent meta-analysis of 13 randomized trials suggested that the harm associated with severe hypoglycemic events (SHEs) could even negate the benefit of intensive glucose reduction [18] . Emergency hospitalizations arising from SHEs represent a considerable economic cost to patients and insurers [19] [20] [21] . Despite the clinical consequences of hypoglycemia and the burden it causes to patients and health-care providers, in one large (n = 3,827) European survey, 65% of people with T1DM and 50-59% of people with T2DM who experienced a nonsevere hypoglycemic event (NSHE) rarely or never informed their physician about hypoglycemia; additionally, among all responders, 17% of those with T1DM and 21-28% with T2DM reported not being asked about hypoglycemia by their physician during routine appointments [22] . Clinically, there may be an impression that the lower frequency of hypoglycemia in T2DM means that it is of lesser clinical importance in that type of diabetes; such an interpretation, however, may not adequately characterize the impact of hypoglycemia in T2DM [8, 9, 23] .
Given this background, understanding the constellation of factors predisposing to hypoglycemia, and SHEs in particular, is of considerable clinical importance [24] . One of the most consistently reported risk factors for SHEs is a history of prior SHEs [7] . For example, in one observational study of 267 patients with insulin-treated diabetes, statistically significant predictors of hypoglycemia in T1DM included a history of previous hypoglycemia (P = 0.006) and co-prescribing of any oral medication (P = 0.048) [7] . For T2DM, a history of previous hypoglycemia (P = 0.0001) and duration of insulin treatment (P = 0.014) were significant. NSHEs, for which third-party assistance is not required, occur far more commonly than SHEs; however, the clinical and economic relevance of such events may be underappreciated, especially in T2DM. In particular, there is a lack of data reflecting the potential association between NSHEs and SHEs.
The aim of this study was to report data on the co-occurrence of NSHEs and SHEs (without inferring a causal relationship between the two) and, using a regression model, to determine which covariates influence the likelihood of experiencing a SHE.
METHODS

Subjects
PREDICTIVE was a global, prospective, openlabel, observational study of more than 20,000 patients with T1DM or T2DM intended to evaluate the safety and efficacy of insulin detemir in routine clinical practice; details of the study design and primary results have been published [25] [26] [27] . This secondary analysis reports data on the frequency of NSHEs and SHEs, along with their co-occurrence, in insulin-treated patients with T1DM (n = 7,420) or T2DM (n = 12,981) from 11 countries (Austria, Czech Republic, Denmark, Finland, Germany, Ireland, Israel, Netherlands, Sweden, Turkey, and the UK). We selected PREDICTIVE (Clinicaltrials.gov #NCT00659295) for this analysis because it was unique in the systematic way in which NSHEs were recorded and the trial enrolled sufficient numbers of patients to allow analysis of SHEs in people with T2DM. As an observational study, we also believed PREDICTIVE offered the advantage of reflecting real-world practice. The analysis in this article does not involve any new studies of human or animal subjects performed by any of the authors.
Insulin Treatment
Patients entering this study were prescribed insulin detemir (100 U/ml formulation) by their physician as part of routine clinical care and followed up for a mean period of 14.4 weeks. Patients currently using insulin detemir were ineligible. 75% of patients with T1DM were using a basal-bolus regimen at baseline, compared with 25% of those with T2DM. A further 31% of patients with T2DM were using insulin plus OADs and 27% used OADs without insulin. Neutral protamine Hagedorn insulin was the most commonly used basal insulin prior to entering the study (63% T1DM, 66% T2DM), followed by insulin glargine (34% T1DM, 29% T2DM). All decisions about insulin dose, frequency of dosing and other treatments were at the discretion of the patient's physician.
Hypoglycemic Events
Patients reported the number of NSHEs and SHEs experienced during the 4 weeks prior to baseline and during a 4-week period prior to the end of their follow-up visit. SHEs were defined as an episode with symptoms of neuroglycopenia, in which the patient was unable to treat himself/herself and third-party intervention was needed, and where the patient had one of the following characteristics:
(ii) reversal of symptoms after food intake, glucagon or intravenous glucose administration.
Confirmed hypoglycemic events where third-party assistance was not required were classified as NSHEs. SHEs were categorized into 0 versus C1 in frequency, and NSHEs were classified as 0, 1-4, and C5 in frequency, during the two reporting periods.
Statistical Analysis
Demographic variables and baseline diabetes characteristics were summarized with descriptive statistics. Hypoglycemic events were analyzed by severity and frequency (NSHEs: 0, 1-4, C5 events; SHEs: 0 and C1 event). The primary end point of this study was the association between NSHEs and SHEs at baseline and between NSHEs and SHEs at follow-up. Cross-tabulations and the Chisquare test were used to test for statistically significant associations between frequencies of NSHE and SHE, for T1DM and T2DM. 
RESULTS
Patients
Baseline demographics (mean ± SD) of the study population are summarized in Table 1 .
Glycemic control at baseline was similar for both T1DM and T2DM (HbA 1c 8.2 ± 1.6 and 8.5 ± 1.6%, respectively). Glycemic control significantly improved at follow-up which has previously been reported [25] . As might be expected, patients with T1DM were younger and had a longer duration of diabetes and a lower BMI than those with T2DM.
Frequency of Hypoglycemic Events
The proportion of patients providing data concerning the frequency of hypoglycemic events was high ([90%) at baseline (n = 7,399/ 7,420 and n = 12,966/12,981, for T1DM and T2DM, respectively) and at follow-up (n = 6,837/7,420 and 12,368/12,981, for T1DM and T2DM, respectively). Hypoglycemic episodes per patient year have been reported previously [25] . As might be expected, both during the 4-week reporting periods at baseline and at follow-up, a greater proportion of patients with T1DM reported a hypoglycemic event (baseline: T1DM, 4 patients who experienced a SHE at baseline also experienced an event at follow-up. In contrast 1% (T1DM) and 0.2% (T2DM)
experienced a SHE at follow-up without experiencing a SHE at baseline.
In the multiple logistic regression model, longer duration of diabetes was associated with an increased risk of SHEs (P = 0.004) in T1DM, whereas in T2DM, none of the covariates in the adjusted model were statistically significant.
The odds of experiencing a SHE with increasing frequency of NSHEs remained statistically significant (P\0.0001) and increased slightly in magnitude when adjusted for confounders, for either T1DM or T2DM (Fig. 3) . In T1DM, adjusted ORs for experiencing a SHE again changed very little compared to unadjusted estimates (Fig. 3) . However, in T2DM, the association between NSHEs and SHEs was further strengthened, compared to unadjusted estimates, after adjusting for potential confounders (Fig. 2) .
DISCUSSION
These observational data, from a large cohort of patients with T1DM or T2DM in 11 countries (PREDICTIVE study) using insulin detemir in a Fig. 1 Hypoglycemic events recorded during 4 weeks before baseline and 4 weeks before follow-up, for type 1 and type 2 diabetes mellitus, in the PREDICTIVE study. NSHE non-severe hypoglycemic event, SHE severe hypoglycemic event setting of routine care provide confirmation of a strong association between the occurrence of NSHEs and SHEs. Importantly, the odds of experiencing C1 SHE increased with increasing frequency of NSHEs (i.e., 0, 1-4 and C5 events), both at baseline and at follow-up. This supports the notion that NSHEs could predispose to SHEs, a concept that is supported by the Fig. 2 Adjusted odds ratio estimates for experiencing C1 SHEs for T1DM (top) and T2DM (bottom), at baseline in the PREDICTIVE study. P values are for the covariate named on the left. BMI body mass index, CI confidence interval, HbA 1c glycosylated hemoglobin, NSHE non-severe hypoglycemic event, SHE severe hypoglycemic event, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus relationship between NSHEs and SHEs being maintained despite adjustment for potential confounders, both in patients with T1DM and T2DM.
As previously reported for the PREDICTIVE study, the absolute frequency of NSHEs and SHEs all decreased significantly from baseline (P\0.0001) [25] . Despite this decrease in lower frequency of SHEs (compared to T1DM) was tempered once any NSHE was reported.
An interesting finding was that the effect of increasing frequency of NSHEs on odds of having C1 SHEs was much greater in T2DM than in T1DM, being at least fivefold greater at baseline and more than eightfold greater at follow-up. The odds of C1 SHE were increased from 10-to 25-fold for patients with T2DM who reported NSHEs, whereas the odds of C1 SHE increased only about 2-to 3-fold for patients with T1DM who reported NSHEs (Figs. 2, 3 ).
This further highlights the relevance of hypoglycemia in T2DM, which, as others have noted [8] , may be underappreciated and highlights the need to adopt strategies directed toward the reduction of both severe and non-severe hypoglycemia in patients with both T1DM and T2DM. Furthermore, our analysis indicates that overweight people with T2DM (BMI[35 kg/m 2 ) seemed to have a lower frequency of both NSHE and SHE which can be explained by increasing insulin resistance. Potential mechanisms that may account for the association between NSHEs and SHEs observed in our analysis may relate to the effect of recurrent symptomatic hypoglycemia with respect to blunted subsequent counterregulatory hormone secretion [28] . Our data may also reflect an extension of observations from the Action In Diabetes And Vascular
Disease: Preterax And Diamicron Modified
Release Controlled Evaluation (ADVANCE; ClinicalTrials.gov #NCT00145925) study [15] , suggesting a clustering of hypoglycemia in susceptible individuals.
This study supports other data evaluating the relevance of non-severe hypoglycemia. Indeed, NSHEs have a significant detrimental effect on patients' quality of life, adherence to prescribed insulin doses and workplace productivity [1] .
This was recently demonstrated from a survey of people with diabetes in the USA, UK, Germany and France, where over a 1-month period, mean losses in workplace productivity were estimated to range from $US15.26-93.47 in relation to each NSHE. The cost of hospital treatment of a SHE is considerably greater. In one study of 639 patients in Germany, Spain and the UK, costs per SHE averaged $US304-693 per event [20] .
Limitations
Data concerning the incidence of either NSHEs or SHEs in this study must be interpreted with the understanding that hypoglycemic events were only reported during a 4-week period at baseline and a 4-week period at the end of the study. Due to the study design, it is not possible to determine whether increased frequency of 
